AI Verdict
INFY has stronger fundamentals based on our AI analysis.
INO vs INFY Fundamental Comparison
| Metric | INO | INFY |
|---|---|---|
| Revenue | $65,343.0 | N/A |
| Net Income | $-84.9M | N/A |
| Net Margin | -130,000.0% | N/A |
| ROE | -352.5% | N/A |
| ROA | -114.3% | N/A |
| Current Ratio | 1.40x | N/A |
| Debt/Equity | 2.60x | N/A |
| EPS | $-1.81 | N/A |
Green = Better metric | Red = Weaker metric
You Might Also Compare
INO vs INFY: Frequently Asked Questions
Is INO or INFY a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), INFY has stronger fundamentals. INO is rated STRONG SELL (92% confidence) while INFY is rated HOLD (5% confidence). This is not investment advice.
How does INO compare to INFY fundamentally?
INOVIO PHARMACEUTICALS, INC. has ROE of -352.5% vs Infosys Ltd's N/A. Net margins are -130,000.0% vs N/A respectively.
Which stock pays higher dividends, INO or INFY?
INO has a dividend yield of N/A or no dividend while INFY has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in INO or INFY for long term?
For long-term investing, consider that INO has STRONG SELL rating with 92% confidence, while INFY has HOLD rating with 5% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about INO vs INFY?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For INO vs INFY, the AI consensus favors INFY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.